<DOC>
	<DOCNO>NCT02426151</DOCNO>
	<brief_summary>To Compare Pharmacokinetic Pharmacodynamic Profiles BEPO-A REPO-A Healthy Male Subjects</brief_summary>
	<brief_title>Bioequivalence Single Subcutaneous Dose BEPO REPO Healthy Male Subjects</brief_title>
	<detailed_description>To Compare Pharmacokinetic Pharmacodynamic Profiles EPO ( BEPO-A ( 4000 IU ) ) EPO ( REPO-A ( 4000 IU ) ) Healthy Male Subjects</detailed_description>
	<criteria>Agree purpose study sign date Informed Consent ; Male , age 19 40 year , clinically healthy ; BMI 19 28 ; 90 mmHg ≤ SBP &lt; 140 mmHg , 50 mmHg ≤ DBP &lt; 85 mmHg Hemoglobin &lt; 13 g / dL Ferritin &lt; 20 ng/mL TIBC &gt; 360 ug/ dL Vitamin B12 &lt; 200 pg/mL floate &lt; 4 ng/mL % reticulpcyte &gt; 3 % platelet &lt; 100,000/ul &gt; 400,000/ul GFR &lt; 60mL/min/1.73m2 Going treatment tumor Clinical history allergy biological product derive mammalian albumin component formulation Clinical history autoimmune hereditary anemia A Positive reaction nicotine test Principal Investigator study criterion .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>